22CM
VIRX

20/20 Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

20/20 Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,857
Closed -$29K – 165
2020
Q4 		$29K Buy
+2,857
New +$14.9K 0.01% 161

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

20/20 Capital Management's VIRX Position: Q1 2021 in Review

20/20 Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2021, closing a stake of 2,857 shares — an estimated $29K sold.

20/20 Capital Management first reported a position in VIRX in Q4 2020 and held it in 1 quarter. The position peaked at $29K in Q4 2020. 50 funds tracked by Wall St. Rank hold VIRX as of Q1 2021.

  • 20/20 Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • 20/20 Capital Management sold 2,857 Viracta Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $29K.
  • 20/20 Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • 20/20 Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $29K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2021.

Based on 20/20 Capital Management's 13F filing for Q1 2021, filed 12 May 2021.